These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24277152)

  • 21. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes.
    Su B; Xu K; Lederle A; Peressin M; Biedma ME; Laumond G; Schmidt S; Decoville T; Proust A; Lambotin M; Holl V; Moog C
    Blood; 2012 Nov; 120(18):3708-17. PubMed ID: 22955927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals.
    Blazkova J; Refsland EW; Clarridge KE; Shi V; Justement JS; Huiting ED; Gittens KR; Chen X; Schmidt SD; Liu C; Doria-Rose N; Mascola JR; Heredia A; Moir S; Chun TW
    J Clin Invest; 2019 Nov; 129(11):4832-4837. PubMed ID: 31589168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
    Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.
    Su B; Lederle A; Laumond G; Ducloy C; Schmidt S; Decoville T; Moog C
    J Virol; 2014 Sep; 88(18):10975-81. PubMed ID: 24965460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells.
    Massanella M; Puigdomènech I; Cabrera C; Fernandez-Figueras MT; Aucher A; Gaibelet G; Hudrisier D; García E; Bofill M; Clotet B; Blanco J
    AIDS; 2009 Jan; 23(2):183-8. PubMed ID: 19098487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
    van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.
    Chun TW; Murray D; Justement JS; Blazkova J; Hallahan CW; Fankuchen O; Gittens K; Benko E; Kovacs C; Moir S; Fauci AS
    Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13151-6. PubMed ID: 25157148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.
    McCoy LE; Groppelli E; Blanchetot C; de Haard H; Verrips T; Rutten L; Weiss RA; Jolly C
    Retrovirology; 2014 Oct; 11():83. PubMed ID: 25700025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity.
    Lorin V; Malbec M; Eden C; Bruel T; Porrot F; Seaman MS; Schwartz O; Mouquet H
    Mucosal Immunol; 2017 May; 10(3):814-826. PubMed ID: 27966557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
    Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
    J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
    Hoot S; McGuire AT; Cohen KW; Strong RK; Hangartner L; Klein F; Diskin R; Scheid JF; Sather DN; Burton DR; Stamatatos L
    PLoS Pathog; 2013 Jan; 9(1):e1003106. PubMed ID: 23300456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.
    Liu L; Wang W; Matz J; Ye C; Bracq L; Delon J; Kimata JT; Chen Z; Benichou S; Zhou P
    J Virol; 2016 Dec; 90(23):10642-10659. PubMed ID: 27654286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4
    Zhang G; Campbell GR; Zhang Q; Maule E; Hanna J; Gao W; Zhang L; Spector SA
    mBio; 2020 Sep; 11(5):. PubMed ID: 32934078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies.
    Martin-Gayo E; Gao C; Chen HR; Ouyang Z; Kim D; Kolb KE; Shalek AK; Walker BD; Lichterfeld M; Yu XG
    Cell Rep; 2020 Jan; 30(4):984-996.e4. PubMed ID: 31995767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
    Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
    Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.